Saad Z. Usmani: Restarting Teclistamab and Talquetamab After Prolonged Dose
Saad Z. Usmani, Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, posted on X about recent paper by Carlyn R Tan et al., titled “Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing” published on Blood Advances.
Authors: Carlyn R Tan, Alice X Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand, Issam S. Hamadeh, Kylee H. Maclachlan, Malin L Hultcrantz, Hani Hassoun, Sham Mailankody, Alexander M Lesokhin, Urvi A Shah, Sridevi Rajeeve, Hamza Hashmi, Dhwani Patel, Ross S Firestone, Eric Matthew Jurgens, Kevin C. Miller, Gunjan L Shah, Michael Scordo, Heather J Landau, Sergio A. Giralt, Neha Korde, Saad Z Usmani
“Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing – the MSK experience.”
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared this post on X, adding:
“Congrats Carlyn R Tan et al!
We always talk about spacing out multiple myeloma-specific bispecific antibodies (MMsm bsAb) to every 4 weeks (Q4W), in order to reduce infections, dysgeusia, and other side effects.
One counterargument was that doing so would require repeat SUD per USPI… but thanks to this in Blood Advances, we know it doesn’t!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023